01
GLP-1
GLP-1 signalling affects satiety, gastric emptying and glucose-dependent insulin response.
GLP-1 receptor agonist
Semaglutide
GLP-1
Semaglutide is a long-acting GLP-1 receptor agonist with approved medicines for specific indications. Its evidence base includes large trials of glycaemia, weight and cardiovascular outcomes; grey-market vials are not equivalent to registered formulations.
1Overview
1× / wkReference frequency
DataLarge phase 3 and outcomes trials
Research status
Approved for specific diabetes, obesity and risk-reduction indications
SEMAGLUTIDE10 MG
01 · Overview
What is Semaglutide?
Semaglutide is a long-acting GLP-1 receptor agonist with approved medicines for specific indications. Its evidence base includes large trials of glycaemia, weight and cardiovascular outcomes; grey-market vials are not equivalent to registered formulations.
Research route, formulation and population determine what a result actually means.
02 · Research
What do the studies show?
Large phase 3 and outcomes trials. Educational information. Not diagnosis, treatment or use advice.
14.9%
Phase 3STEP 1
In 1,961 adults without diabetes, mean weight change at 68 weeks was −14.9% with 2.4 mg versus −2.4% with placebo.
20%
Phase 3Cardiovascular outcomes
SELECT found a relative reduction in major cardiovascular events in people with overweight or obesity and established cardiovascular disease.
03 · DATA
Peptide and product specifications
Checked identity data for this research compound or blend.
SemaglutidePeptide and product specifications
Development code
NN9535
Developer
Novo Nordisk
Molecular formula
C₁₈₇H₂₉₁N₄₅O₅₉
Molecular weight
4113.58 Da
CAS number
910463-68-2
Amino-acid sequence / components
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEA₂-γGlu-C18-diacid)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly
Amino-acid count
31
Modified residues
Aib at position 2; C18 fatty-diacid linker at Lys²⁰; Arg at position 28
Purity
Batch-specific - confirm identity and purity with the Velora COA
Reference diluent
Registered semaglutide medicines are ready-made formulations; a research vial is not equivalent
Unreconstituted-material storage
Follow the accompanying COA, product label and validated stability data
These are compound references, not a batch certificate. Purity and identity of a specific Velora batch must be confirmed by its accompanying COA and laboratory report.
Official FDA prescribing information ↗04 · Calculator
Reconstitution and U-100 conversion
This module only converts concentration and volume. Inputs are not recommendations or individual dosing advice.
Calculator
Once weekly for registered injectable products
1
2
3
4
Draw to
0 units
0.00 mL
SEMAGLUTIDE
10 MG
Concentration-
Per unit-
Complete amounts-
Calculated duration-
LAB · RECONSTITUTION
How to reconstitute Semaglutide for laboratory research
A visual workflow for controlled laboratory reconstitution. Always follow the product label, COA and a validated protocol.
Clean
Disinfect the rubber closures of both vials and allow them to dry.
Measure diluent
Withdraw only the diluent validated for the specific compound.
Add slowly
Let the liquid run slowly down the inside wall of the vial.
Swirl gently
Do not shake; rotate gently until the material has dissolved.
Store per protocol
Follow the product label, COA and validated stability data.
Important checks before and after reconstitution
Check the product
First confirm that the product is a lyophilised vial. Prefilled pens and ready-to-use solutions do not require reconstitution. Check the label, COA and specified diluent.
Use clean, sterile technique
Wash your hands, clean the work surface and use new sterile equipment for every procedure. Clean both rubber closures with separate alcohol swabs and let them dry completely.
Concentration, not total amount
The volume of liquid added changes the concentration in mg per mL, but not the total amount of research compound in the vial. Use the calculator to check this in advance.
Inspect and label
Check for unexpected discoloration, cloudiness or visible particles. Record the compound, concentration and reconstitution date. Storage time and temperature are product-specific; a fixed 28-day rule does not apply to every compound.
General reconstitution volumes listed by the source
General examples, not a product-specific protocol. The chosen volume determines concentration; always check the label, COA and calculator.
| Vial strength | Commonly listed volume |
|---|---|
| 2 mg | 1–2 mL |
| 5 mg | 2–3 mL |
| 6 mg | 2–3 mL |
| 10 mg | 2–4 mL |
| 15 mg | 3–5 mL |
| 20 mg | 4–8 mL |
Practical background source: Free Medical Journals - Complete Step-by-Step Guide to Peptide Reconstitution, accessed July 2026. This is a secondary educational source; the product label, COA and validated stability data remain authoritative.
05 · Safety and limitations
Safety and limitations
Research route, formulation and population determine what a result actually means.
What is known
- Visible research claims use primary or official sources.
- The calculator is arithmetic and does not turn a study amount into medical advice.
- A registered medicine and a research vial are not automatically equivalent.
What remains uncertain
- Many products lack long-term safety data and independent replication.
- Animal and cell findings do not predict a safe human dose.
- Stability depends on formulation, pH, sterility, light, temperature and packaging.
Status: Approved for specific diabetes, obesity and risk-reduction indications. Educational information. Not diagnosis, treatment or use advice.
06 · FAQ
Frequently asked questions
Semaglutide is a long-acting GLP-1 receptor agonist with approved medicines for specific indications. Its evidence base includes large trials of glycaemia, weight and cardiovascular outcomes; grey-market vials are not equivalent to registered formulations.
In 1,961 adults without diabetes, mean weight change at 68 weeks was −14.9% with 2.4 mg versus −2.4% with placebo. SELECT found a relative reduction in major cardiovascular events in people with overweight or obesity and established cardiovascular disease.
No. It performs arithmetic conversions only. Medical decisions belong with a licensed healthcare professional.
The curve follows the agreed storage model and is not a laboratory result.
2–8 °C. Protect from light and repeated freeze-thaw cycles.
07 · Sources
Primary research sources
Educational information. Not diagnosis, treatment or use advice.